Flight of the navigators

Sales in pharma is a frequently changing canvass. Its leveraging of technology has triggered new, bold approaches, while also upholding a fine tradition of individuality among its multifarious and talented workforce. Finding the most compelling mix of human attributes and digital dynamism holds the key to sustained pharma sales success – indeed, it is an industry artform
A new approach to major health conditions

Steve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long Term Plan’s vision to deliver more preventative, joined-up services for key illnesses
Going virtual?

Lindsay McNair and Josh Rose explore the status quo for virtual clinical trials

News

View all

RCGP plea to avoid no-deal Brexit

A no-deal Brexit should be avoided 'at any cost', according to the College

17th June 2019

Greater Manchester joins Cities Changing Diabetes initiative

The city is the second in the UK to join the Novo Nordisk led partnership programme

17th June 2019

Amgen unveils five-year survival data for Blincyto

Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note

17th June 2019

AZ' Calquence shows PFS benefit in CLL patients

A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year

17th June 2019

GSK, Uni of California pair up to advance genomic research

The LGR will receive up to $67 million in funding over a five-year period.

14th June 2019

Web Exclusives

View all

SmartPeople: Dr Vlado Perkovic

Dr Vlado Perkovictalks to PharmaTimes about his hopes for Novo Nordisk’s FLOW trial, and the need to tackle the growing burden of chronic kidney disease (CKD) in the type II diabetes population.

Are PCSK9 inhibitors about to take off?

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.

Outward looking UK scientists among global leaders in the fight against melanoma

Elsevier's Maria de Kleijn-Lloyd looks at UK researchers’ contribution to the fight against melanoma

Will healthcare be a casualty of the EU’s populist surge?

With EU parliament elections fast approaching, Nick Hoile, director of Government Affairs at Publicis Resolute, considers the potential impact of a more Eurosceptic climate on health.

Magazine

View more from the latest edition

Patient Files: Malaria

Laurie Griffiths contracted malaria while travelling in Africa. He tells PharmaTimes his story

Company focus: bluebird bio

Andrew Obenshain, senior vice president and head of Europe at bluebird bio, introduces the company and discusses the challenges and opportunities of gene therapy

A collaborative approach

The viability and value of continuous bioprocessing is now irrefutable, but pharma will need to work with regulators and get the right data to overcome any roadblocks

A roadmap to navigate telehealth

The business potential of telehealth is tremendous in a world in which quality and access to care are of growing importance, but the new challenges it poses cannot be addressed within the borders of our traditional areas of the law

Early access

Lorenzo D’Angelo on strategies for implementing successful pre-launch access programmes

Flight of the navigators

Sales in pharma is a frequently changing canvass. Its leveraging of technology has triggered new, bold approaches, while also upholding a fine tradition of individuality among its multifarious and talented workforce. Finding the most compelling mix of human attributes and digital dynamism holds the key to sustained pharma sales success – indeed, it is an industry artform